Abstract: The swift expansion of e-commerce has demanded the creation of strong, adaptable, and user- friendly platforms. This study looks at building an e- commerce platform with the MERN stack, ...

Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026 Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact.